September 29, 2014 / 11:54 PM / 3 years ago

Valeant Pharmaceuticals sees third-quarter sales boost

Sept 29 (Reuters) - Valeant Pharmaceuticals International Inc, which is pursuing a hostile takeover offer for Allergan Inc, on Monday said it expects sales to rise 15 percent in the third quarter but will face a tougher fourth-quarter comparison to year-ago results.

Valeant, which completed the $8.7 billion purchase of Bausch & Lomb on Aug. 6, 2013, said its third-quarter sales reflect a weak year-ago period for the contact lens maker.

The Canadian company did not give a specific fourth-quarter forecast.

Allergan, the maker of Botox anti-wrinkle injections, has criticized Valeant's acquisition-based business model as it attempts to fend off the drugmaker's $51 billion hostile bid.

Reporting by Susan Kelly in Chicago; Editing by Lisa Shumaker

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below